Pediatric Praziquantel Consortium

World Health Day: Working towards universal health coverage in Africa

03 April 2019

The Pediatric Praziquantel Consortium marks the World Health Day through its continuous effort to register and...

From Africa to Asia: Important dialogues for the Pediatric Praziquantel Consortium

25 February 2019

Consortium partners have been interacting with the local community in Ivory Coast and with experts from all over the...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more